+

WO2008116385A1 - Dérivés d'acide caféyl quinique contenant de l'azote, et procédé de préparation, composition pharmaceutique et leur utilisation - Google Patents

Dérivés d'acide caféyl quinique contenant de l'azote, et procédé de préparation, composition pharmaceutique et leur utilisation Download PDF

Info

Publication number
WO2008116385A1
WO2008116385A1 PCT/CN2008/000562 CN2008000562W WO2008116385A1 WO 2008116385 A1 WO2008116385 A1 WO 2008116385A1 CN 2008000562 W CN2008000562 W CN 2008000562W WO 2008116385 A1 WO2008116385 A1 WO 2008116385A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
virus
formula
hydrate
Prior art date
Application number
PCT/CN2008/000562
Other languages
English (en)
Chinese (zh)
Inventor
Zhanggui Wu
Wei Wei
Original Assignee
Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory filed Critical Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
Priority to US12/532,763 priority Critical patent/US8722725B2/en
Priority to EP08715014.0A priority patent/EP2128125B1/fr
Publication of WO2008116385A1 publication Critical patent/WO2008116385A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • Another object of the present invention is also a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the above compound or a salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés d'acide caféyl quinique et leur procédé de préparation, une composition pharmaceutique les contenant et leur utilisation pour le traitement ou la prophylaxie de la virose, en particulier l'utilisation pour le traitement ou la prophylaxie du virus syncytial respiratoire et du virus de l'hépatite B, qui présente des avantages de sécurité, d'efficacité élevée et de faible toxicité.
PCT/CN2008/000562 2007-03-23 2008-03-21 Dérivés d'acide caféyl quinique contenant de l'azote, et procédé de préparation, composition pharmaceutique et leur utilisation WO2008116385A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/532,763 US8722725B2 (en) 2007-03-23 2008-03-21 Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof
EP08715014.0A EP2128125B1 (fr) 2007-03-23 2008-03-21 Dérivés d'acide caféyl quinique contenant de l'azote, et procédé de préparation, composition pharmaceutique et leur utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200710086601.9 2007-03-23
CN200710086601 2007-03-23
CN2008100843914A CN101284799B (zh) 2007-03-23 2008-03-20 咖啡酰奎宁酸含氮衍生物及其制备方法和其药物组合物及用途
CN200810084391.4 2008-03-20

Publications (1)

Publication Number Publication Date
WO2008116385A1 true WO2008116385A1 (fr) 2008-10-02

Family

ID=39788039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/000562 WO2008116385A1 (fr) 2007-03-23 2008-03-21 Dérivés d'acide caféyl quinique contenant de l'azote, et procédé de préparation, composition pharmaceutique et leur utilisation

Country Status (4)

Country Link
US (1) US8722725B2 (fr)
EP (1) EP2128125B1 (fr)
CN (1) CN101284799B (fr)
WO (1) WO2008116385A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008323683B2 (en) * 2007-11-09 2014-10-02 University Of Tennessee Research Foundation Anti-inflammatory quinic acid derivatives for oral administration
WO2023212353A1 (fr) * 2022-04-29 2023-11-02 Emory University Inhibiteurs de l'entrée de virus dérivés de plantes

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
CN101284799B (zh) 2007-03-23 2013-04-03 浙江医药股份有限公司新昌制药厂 咖啡酰奎宁酸含氮衍生物及其制备方法和其药物组合物及用途
CN101397333A (zh) * 2007-09-27 2009-04-01 浙江医药股份有限公司新昌制药厂 去羟基万古霉素及其制备方法、和其药物组合物及其用途
CN101595977B (zh) * 2008-06-02 2013-04-03 浙江医药股份有限公司新昌制药厂 有益于眼睛明视持久度的配方食品及其应用
CN101828693B (zh) 2009-03-09 2013-01-02 浙江医药股份有限公司新昌制药厂 制备低粘度高流动性类胡萝卜素油悬浮液的方法及其应用
US9126968B2 (en) * 2013-06-13 2015-09-08 National Applied Research Laboratories Quinic acid derivative, process for preparation and uses thereof
CN104761464B (zh) * 2014-01-03 2017-08-04 陈惠民 一种奎尼酸衍生物、其制程及其用途
CN104644711B (zh) * 2014-11-21 2018-05-22 暨南大学 一种艾纳香属植物提取物及其制备方法与应用
CN105130838A (zh) * 2015-07-15 2015-12-09 遵义医学院 一种绿原酸酰胺衍生物及其合成、应用
FR3050455B1 (fr) 2016-04-26 2019-06-14 Temisis Derives amides des acides polycafeoylquiniques, procede de preparation et utilisations
CN111423407B (zh) * 2019-01-10 2021-06-08 中国医学科学院药用植物研究所 一种咖啡酰奎宁酸类衍生物及其制备方法和用途
CN110156628B (zh) * 2019-06-19 2022-05-17 暨南大学 一种环三醇衍生物及其制备方法与应用
CN110218160B (zh) * 2019-06-19 2022-05-24 暨南大学 一种奎宁酸衍生物及其制备方法与应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577516A1 (fr) 1992-07-01 1994-01-05 L'oreal Composition cosmétique et/ou dermatologique à action dépigmentante contenant un acide di- ou tri-caféoylquinique ou un mélange de ceux-ci
CN1087608A (zh) 1992-10-30 1994-06-08 赖因哈特·冯·诺登斯克耶尔德 净化废水的方法和设备
CN1136434A (zh) 1996-02-13 1996-11-27 云南安泰高新技术公司 二咖啡酰氧基奎宁酸在制药中的应用
CN1175411A (zh) * 1996-08-29 1998-03-11 中国人民解放军军事医学科学院放射医学研究所 二咖啡酰奎宁酸在治疗乙型肝炎及与逆转录病毒有关疾病中的用途及新咖啡酰奎宁酸衍生物
EP1200462A2 (fr) * 1999-07-30 2002-05-02 Centre National De La Recherche Scientifique (Cnrs) Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose
US20020111382A1 (en) 2000-09-06 2002-08-15 Xiangmin Cui Antiviral compounds and method of treating viral infections
CN1476842A (zh) 2003-07-15 2004-02-25 中国人民解放军第二军医大学 灯盏花素和二咖啡酰奎宁酸药物组合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918477A (en) * 1954-12-28 1959-12-22 Alberti Carlo Giuseppe Caffeic esters of quinic acid and quinic acid amide and syntheses thereof
DE3572178D1 (en) 1984-04-16 1989-09-14 Lilly Co Eli Improvements in and relating to antibiotics m43a, m43b, m43c and m43d
EG18377A (en) 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
WO1998009964A1 (fr) 1996-09-03 1998-03-12 Bristol-Myers Squibb Company PROCEDE DE PREPARATION AMELIORE DE L'AGENT ANTIVIRAL [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE-CYCLOPENTYL]-6-H-PURINE-6-ONE
CN1093529C (zh) * 1999-04-16 2002-10-30 中国人民解放军军事医学科学院放射医学研究所 1，5－二－o－咖啡酰奎宁酸衍生物的制备方法
US6355616B1 (en) * 1999-06-25 2002-03-12 Xoma (Us) Technology Ltd. Derivative compounds derived from or based on bactericidal/permeability-increasing protein
CN1415758A (zh) 2001-10-30 2003-05-07 上海医药工业研究院 盐酸万古霉素原料生产工艺
DK1644384T3 (da) 2002-12-11 2013-02-11 Bristol Myers Squibb Co Fremgangsmåde og mellemprodukter til syntese af entecavir
CN100363484C (zh) 2004-02-16 2008-01-23 华北制药集团有限责任公司 一种河北拟无枝菌酸菌菌株以及利用该菌株发酵制备盐酸去甲万古霉素
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP2006298802A (ja) * 2005-04-19 2006-11-02 Yoshihiro Futamura 血管弛緩作用を呈するクロロゲン酸誘導体とアルギニンとのエステル結合体、それを含有する食品製剤及び化粧品
US20070060599A1 (en) 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
WO2008009138A1 (fr) * 2006-07-21 2008-01-24 Genesis Group Inc. Dérivés de l'acide chlorogénique et leur utilisation comme agents anti-fongiques
CN101245068A (zh) 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
CN101284799B (zh) 2007-03-23 2013-04-03 浙江医药股份有限公司新昌制药厂 咖啡酰奎宁酸含氮衍生物及其制备方法和其药物组合物及用途
CN101397333A (zh) 2007-09-27 2009-04-01 浙江医药股份有限公司新昌制药厂 去羟基万古霉素及其制备方法、和其药物组合物及其用途
AU2008323683B2 (en) * 2007-11-09 2014-10-02 University Of Tennessee Research Foundation Anti-inflammatory quinic acid derivatives for oral administration

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577516A1 (fr) 1992-07-01 1994-01-05 L'oreal Composition cosmétique et/ou dermatologique à action dépigmentante contenant un acide di- ou tri-caféoylquinique ou un mélange de ceux-ci
US5445816A (en) 1992-07-01 1995-08-29 L'oreal Depigmenting cosmetic and/or dermatological composition containing a di- or tri-caffeoylquninic acid, or a mixture thereof
CN1087608A (zh) 1992-10-30 1994-06-08 赖因哈特·冯·诺登斯克耶尔德 净化废水的方法和设备
CN1136434A (zh) 1996-02-13 1996-11-27 云南安泰高新技术公司 二咖啡酰氧基奎宁酸在制药中的应用
CN1175411A (zh) * 1996-08-29 1998-03-11 中国人民解放军军事医学科学院放射医学研究所 二咖啡酰奎宁酸在治疗乙型肝炎及与逆转录病毒有关疾病中的用途及新咖啡酰奎宁酸衍生物
EP1008344A2 (fr) 1996-08-29 2000-06-14 Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla Utilisation d'un nouvel acide bicafeoylquinique dans le traitement de l'hepatite b et des maladies liees a des retrovirus, et derives de cet acide bicafeolyquinique
US6331565B1 (en) 1996-08-29 2001-12-18 Institute Of Radiation Medicine Academy Of Military Medical Sciences Of The Pla Dicaffeoylquinic acid for treating hepatitis B and the diseases associated with retrovirus, and the new caffeoylquinic acid derivatives
EP1200462A2 (fr) * 1999-07-30 2002-05-02 Centre National De La Recherche Scientifique (Cnrs) Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose
US20020111382A1 (en) 2000-09-06 2002-08-15 Xiangmin Cui Antiviral compounds and method of treating viral infections
CN1476842A (zh) 2003-07-15 2004-02-25 中国人民解放军第二军医大学 灯盏花素和二咖啡酰奎宁酸药物组合物及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of EP2128125A4 *
YANRONG SUN; JUNXING DONG ET AL., BULLETIN OF THE ACADEMY OF MILITARY MEDICAL SCIENCES, vol. 26, no. 1, 2002, pages 39
YOSHIMOTO M. ET AL., BIOSCI BIOTECHNOL BIOCHEM, vol. 66, no. 11, 2002, pages 2336

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008323683B2 (en) * 2007-11-09 2014-10-02 University Of Tennessee Research Foundation Anti-inflammatory quinic acid derivatives for oral administration
WO2023212353A1 (fr) * 2022-04-29 2023-11-02 Emory University Inhibiteurs de l'entrée de virus dérivés de plantes

Also Published As

Publication number Publication date
EP2128125B1 (fr) 2015-05-06
EP2128125A1 (fr) 2009-12-02
CN101284799A (zh) 2008-10-15
EP2128125A4 (fr) 2010-03-31
US20100144828A1 (en) 2010-06-10
CN101284799B (zh) 2013-04-03
US8722725B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
WO2008116385A1 (fr) Dérivés d'acide caféyl quinique contenant de l'azote, et procédé de préparation, composition pharmaceutique et leur utilisation
KR102771082B1 (ko) 케토아미드계 화합물 및 이의 제조 방법, 약학 조성물과 용도
TWI424841B (zh) 5-乙醯胺基-4-胍基-9-o-辛醯基-2,3,4,5-四去氧-7-o-甲基-d-甘油基-d-半乳糖基-壬-2-烯吡喃糖酸用於製造h5n1型流行性感冒治療劑或預防劑之使用
ES2741444T3 (es) Inhibidores de la replicación de virus de la gripe
CN114426568A (zh) 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途
US20240285598A1 (en) Compounds for the treatment of sars
CN102526087B (zh) 核苷类化合物在制备治疗肠病毒71(ev71)感染疾病药物的应用
RU2436786C1 (ru) Замещенные индолы, противовирусный активный компонент, способ получения и применения
CN107266404A (zh) 一种神经氨酸酶抑制剂扎那米韦衍生物及其制备方法
WO2024234474A1 (fr) Dérivé deutéré d'hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine, composition pharmaceutique de celui-ci, procédé de préparation correspondant et utilisation anti-grippe associée
CN114014856A (zh) 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物
WO2021049980A1 (fr) Nouvelles formulations pour le traitement et la prévention de maladies virales
CN101260077B (zh) 喹啉-2-酮类衍生物，其药物组合物及其用途
CN101328123B (zh) 5-氧-取代苯烯丙酰奎尼酸甲酯化合物及其用途
RU2726119C1 (ru) Новые производные полиолов, их применение, фармацевтическая композиция на их основе
RU2746692C1 (ru) Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
CN114805141A (zh) 4-胍基苯甲酸芳基酯类化合物及其在抗SARS-CoV-2病毒中的用途
CN108948084B (zh) 替诺福韦双-l-氨基酸酯及其制备方法
RU2745265C2 (ru) Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
CN118806753B (zh) 异吲哚酮类化合物在制备抗病毒药物中的应用
RU2776839C2 (ru) Новые производные полиолов, их применение, фармацевтическая композиция на их основе
RU2782532C2 (ru) Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
RU2791902C2 (ru) Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
CN114053394B (zh) 新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用
WO2004080453A1 (fr) Agent anti-virus de l'hepatite c et agent anti-vih

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715014

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008715014

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12532763

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载